VISIT OUR COVID-19 HUB

Your Health
GettyImages-1208505315_790x500_1_0.png
GettyImages-1208505315_1000x450_0_0_0.jpg

VISIT OUR COVID-19 HUB

Sharing resources to stay safe and updates on our efforts we hope could bring an end to the global health crisis.

Learn More

The Facts About Pfizer and BioNTech’s COVID-19 Vaccine

Our Science
young_woman_getting_vaccinated_380x500.png
young_woman_getting_vaccinated_1000x450.png

The Facts About Pfizer and BioNTech’s COVID-19 Vaccine

The U.S. FDA authorization of the Pfizer-BioNTech COVID-19 vaccine for emergency use is a significant step forward in our fight against this pandemic.

Learn More

COVID-19 SCIENTIFIC RESOURCES

Our Science
COVID-19 SCIENTIFIC RESOURCES
COVID-19 SCIENTIFIC RESOURCES

COVID-19 SCIENTIFIC RESOURCES

Current information on our scientific progress to bring forward a safe and effective vaccine to help protect against the novel coronavirus.

More Here

Empowering Patients by Closing the Health Literacy Gap

Your Health
medical_information_790x500.png
medical_information_1000x450.jpg

Empowering Patients by Closing the Health Literacy Gap

Knowledge is power. By making health information easier to understand, we're working to help patients make meaningful decisions about their health.

Find Out How

Search products

Search products, A–Z

Need help paying for Pfizer medicines?

Find a Trial

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Getting to Know Pfizer’s New Chief Medical Officer Aida Habtezion

Our People
aida_habtezion_380x700.png
Aida-1000x450_1.jpg

Getting to Know Pfizer’s New Chief Medical Officer Aida Habtezion

Changing careers in the middle of a pandemic is no small endeavor. But when Aida Habtezion, M.D., learned about the opportunity to serve as Pfizer’s new Chief Medical Officer, she couldn’t pass it up.

Meet Aida

PFIZER’S COMMITMENT TO PATIENTS REFLECTED IN NEW IP PACT

Our Purpose
IP-Pact tile image mobile
IP-Pact tile image

PFIZER’S COMMITMENT TO PATIENTS REFLECTED IN NEW IP PACT

Understand the way we use IP and why it matters for what we do.

See how we are living up to that commitment

Latest News

Data Published in New England Journal of Medicine…

Trial demonstrates cumulative incidence of death or respiratory failure through day 28 was 18.1% (26 of 144) with tofacitinib compared to 29.0% (42 of 145) with placebo, in hospitalized patients with COVID-19 pneumonia Multi-center, randomized, double-blind, placebo-controlled trial conducted across 15 sites in Brazil Tofacitinib is not approved or authorized for the treatment of COVID-19 patients. Tofacitinib should not be used in patients with an active serious infection Pfizer Inc. (NYSE:…
Read more